Pembrolizumab efficacy and effects

Pembrolizumab's main function is to treat certain types of cancer by enhancing the body's immune system's ability to attack cancer cells. It belongs to the category of immune checkpoint inhibitors and acts on the interaction between PD-1 and PD-L1. Pembrolizumab can dismantle the mechanism by which cancer cells inhibit immune cell attack through the binding of PD-L1 to PD-1. It blocks the binding of the PD-1 receptor to the PD-L1 ligand, thereby restoring the immune system's ability to attack cancer cells.

Pembrolizumab has been approved for the treatment of a variety of cancers, including melanoma, non-small cell lung cancer, renal cancer, and head and neck squamous cell carcinoma. It can be used as part of a first-line or later-line treatment regimen, or in combination with other treatments (such as chemotherapy, radiation therapy). Pembrolizumab can promote immune cells such as T cells, natural killer cells, and macrophages to attack cancer cells. This is of great significance in guiding the body's immune system to actively identify and eliminate cancer. Pembrolizumab has a longer duration and can achieve durable clinical responses in some patients.

PembrolizumabThe original drug is already on the market in China. SpecificationsThe price per box of 100mg/4ml may be around RMB 15,000. This drug is a strictly controlled drug and has not yet been included in medical insurance. Pembrolizumab The price of the European version of the original drug 100mg/4ml per box may be around RMB 25,000, and the price of the Turkish version of 100mg/4ml per box may be around 10,000 RMB (the price may fluctuate due to the exchange rate). The ingredients of the original drugs at home and abroad are basically the same, and they are expensive. There are currently no generic versions of Pembrolizumab available overseas.